NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics |
|
|
| Recruiting | 3 | 882 | Europe | Cytarabine, Daunorubicin, CPX-351 | University of Ulm, Jazz Pharmaceuticals | Acute Myeloid Leukemia | 03/24 | 03/24 | | |
ASPIRE, NCT05254171: Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer |
|
|
| Recruiting | 2/3 | 600 | Europe, US, RoW | SBP-101, ivospemin, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar, Placebo | Panbela Therapeutics, Inc. | Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV | 08/26 | 01/27 | | |
NCT05174650: Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements |
|
|
| Recruiting | 2 | 37 | Europe | Atezolizumab, Tecentriq, Derazantinib, ARQ 087 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Intrahepatic Cholangiocarcinoma | 12/25 | 08/26 | | |
